Genetics of melanoma progression: the rise and fall of cell senescence
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Summary: There are many links between cell senescence and the genetics of melanoma, meaning both familial susceptibility and somatic–genetic changes in sporadic melanoma. For example, CDKN 2A, the best‐known melanoma susceptibility gene, encodes two effectors of cell senescence, while other familial melanoma genes are related to telomeres and their maintenance. This article aimed to analyze our current knowledge of the genetic or epigenetic driver changes necessary to generate a cutaneous metastatic melanoma, the commonest order in which these occur, and the relation of these changes to the biology and pathology of melanoma progression. Emphasis is laid on the role of cell senescence and the escape from senescence leading to cellular immortality, the ability to divide indefinitely.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“When a strong RAS or RAF oncogene is transduced and overexpressed in cultured cells, including melanocytes, the cells tend to stop dividing almost immediately (e.g., Gray-Schopfer et al., 2006; Michaloglou et al., 2005; Serrano et al., 1997).”
BackgroundGenomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096 · cited 2×
“Melanomas have a median of 13–17 mutations per Mbp of DNA, the highest frequency among 21 cancer types analyzed (Hodis et al., 2012; Lawrence et al., 2014; The Cancer Genome Atlas Network, 2015), even without considering rearrangements, copy number alterations, and epigenetic changes.”
BackgroundCellular senescence: from physiology to pathology
Muñoz-Espín, D., & Serrano, M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3823 · Cited by 2,818
Distinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
A landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610 · cited 27×
“…therefore necessary to use careful statistical and functional screening to identify real driver mutations, although the screening criteria vary somewhat between studies and the identified gene set varies in part (Hodis et al., 2012; Krauthammer et al., 2015; The Cancer Genome Atlas Network, 2015).”
BackgroundResultInfluentialRb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence
Narita, M., Nuñez, S., Heard, E., Narita, M., Lin, A. W., Hearn, S. A., Spector, D. L., Hannon, G. J., & Lowe, S. W. (2003) · Cell · doi:10.1016/s0092-8674(03)00401-x · Cited by 2,278 · cited 2×
“This may reflect an admixture of some nonsenescent but quiescent melanocytes, or of cells with senescence maintained by stable gene silencing (Bandyopadhyay et al., 2007; Narita et al., 2003), or there may be (an)other effector(s) able to mediate senescence without p16.”
BackgroundBRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160 · cited 7×
“So do oncogenes in vivo in nevi (not overexpressed) contribute at all to triggering senescence before replicative senescence would normally set in? Despite the evidence from nevus size, genetics and age, it was reported that telomeres in nevus cells are not detectably shorter than those of neighboring stromal cells (M…”
BackgroundInfluentialOncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network
Kuilman, T., Michaloglou, C., Vredeveld, L. C. W., Douma, S., van Doorn, R., Desmet, C. J., Aarden, L. A., Mooi, W. J., & Peeper, D. S. (2008) · Cell · doi:10.1016/j.cell.2008.03.039 · Cited by 2,086 · cited 1×
“…epithelial cells, and drug-treated cancer cells) secrete a large repertoire of cytokines and other inflammation-related factors, such as IL6 and IL1b; also including proteases such as MMP2, angiogenic factors such as VEGFs, and other growth factors (Copp e et al., 2008; Kuilman et al., 2008).”
BackgroundThe essence of senescence: Figure 1.
Kuilman, T., Michaloglou, C., Mooi, W. J., & Peeper, D. S. (2010) · Genes & Development · doi:10.1101/gad.1971610 · Cited by 2,038
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986 · cited 2×
“Telomeres have a protective protein cap, the shelterin complex (Martínez and Blasco, 2011), but when a telomere reaches a critically short length, its cap is destabilized and the DNA end becomes exposed, leading to mis‐recognition of this end as a DNA double‐strand break (Bartkova et al., 2006; Rossiello et al., 2014;…”
BackgroundTERT Promoter Mutations in Familial and Sporadic Melanoma
Horn, S., Figl, A., Rachakonda, P. S., Fischer, C., Sucker, A., Gast, A., Kadel, S., Moll, I., Nagore, E., Hemminki, K., et al. (2013) · Science · doi:10.1126/science.1230062 · Cited by 1,799 · cited 12×
“One melanoma-susceptible family had a germline activating promoter mutation of TERT, encoding telomerase reverse transcriptase, the catalytic subunit of telomerase (Horn et al., 2013).”
BackgroundResultInfluentialExome sequencing identifies recurrent somatic RAC1 mutations in melanoma
Krauthammer, M., Kong, Y., Ha, B. H., Evans, P., Bacchiocchi, A., McCusker, J. P., Cheng, E., Davis, M. J., Goh, G., Choi, M., et al. (2012) · Nature Genetics · doi:10.1038/ng.2359 · Cited by 1,191 · cited 3×
“attributable to chance, again being large genes, with the possible exception of PTPRK (Krauthammer et al., 2012).”
BackgroundBrafV600E cooperates with Pten loss to induce metastatic melanoma
Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky Jr, W. E., You, M. J., DePinho, R. A., McMahon, M., & Bosenberg, M. (2009) · Nature Genetics · doi:10.1038/ng.356 · Cited by 1,189
Cellular Senescence in Aging Primates
Herbig, U., Ferreira, M., Condel, L., Carey, D., & Sedivy, J. M. (2006) · Science · doi:10.1126/science.1122446 · Cited by 1,101 · cited 8×
“…signaling foci, such as 53BP1, cH2AX, and phospho-CHEK2, are becoming accepted as general markers of cell senescence (Cairney et al., 2012; Herbig et al., 2006; Salama et al., 2014). p53 can mediate arrest and senescence through various routes (Salama et al., 2014), but a major…”
BackgroundInfluentialThe signals and pathways activating cellular senescence
Ben-Porath, I., & Weinberg, R. A. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.10.013 · Cited by 1,046 · cited 2×
“This seems surprising as somatic defects in p16 are common in many cancer types (Ben-Porath and Weinberg, 2005; Forbes et al., 2015; Ruas and Peters, 1998).”
BackgroundChien, Y., Scuoppo, C., Wang, X., Fang, X., Balgley, B., Bolden, J. E., Premsrirut, P., Luo, W., Chicas, A., Lee, C. S., et al. (2011) · Genes & Development · doi:10.1101/gad.17276711 · Cited by 1,046
Freund, A., Patil, C. K., & Campisi, J. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.69 · Cited by 1,039 · cited 2×
“depends on NFB RELA (p65) activity and on MAPK14 (p38) (Figure 3), and can function to attract immune effector cells and promote clearance of senescent cells from the body (Chien et al., 2011; Freund et al., 2011; Ohanna et al., 2011).”
BackgroundFeedback between p21 and reactive oxygen production is necessary for cell senescence
Passos, J. F., Nelson, G., Wang, C., Richter, T., Simillion, C., Proctor, C. J., Miwa, S., Olijslagers, S., Hallinan, J., Wipat, A., et al. (2010) · Molecular Systems Biology · doi:10.1038/msb.2010.5 · Cited by 1,019 · cited 5×
“A conserved hexapeptide within ARF was required for this function; interestingly, this sequence is often targeted by familial melanoma mutations in CDKN2A, suggesting that the loss of this ARF function may increase melanoma risk by mutagenicity of ROS (Christensen et al., 2014).”
BackgroundInfluentialHewitt, G., Jurk, D., Marques, F. D. M., Correia-Melo, C., Hardy, T., Gackowska, A., Anderson, R., Taschuk, M., Mann, J., & Passos, J. F. (2012) · Nature Communications · doi:10.1038/ncomms1708 · Cited by 908
Cellular senescence and its effector programs
Salama, R., Sadaie, M., Hoare, M., & Narita, M. (2014) · Genes & Development · doi:10.1101/gad.235184.113 · Cited by 855
Telomeres and telomerase in cancer
Artandi, S. E., & DePinho, R. A. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp268 · Cited by 823 · cited 8×
“Genetic requirements for immortality of human melanocytes Cell immortality, the ability to divide indefinitely, has been described as a hallmark of cancer (Hanahan and Weinberg, 2011)—although actually not all early cancers appear to be immortal (Artandi and DePinho, 2010; Reddel, 2010), as will be discussed.”
BackgroundInfluentialMelanoma genome sequencing reveals frequent PREX2 mutations
Berger, M. F., Hodis, E., Heffernan, T. P., Deribe, Y. L., Lawrence, M. S., Protopopov, A., Ivanova, E., Watson, I. R., Nickerson, E., Ghosh, P., et al. (2012) · Nature · doi:10.1038/nature11071 · Cited by 756 · cited 2×
“A related player is PREX2, an inhibitor of PTEN (Figure 2; Table 1), recently reported to become a melanoma driver by common activating mutations (16% of melanomas) (Berger et al., 2012); thus PREX2 activation would be broadly equivalent to PTEN loss.”
BackgroundForkhead box proteins: tuning forks for transcriptional harmony.
Lam, E. W.-F., Brosens, J. J., Gomes, A. R., & Koo, C.-Y. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3539 · Cited by 684 · cited 5×
“However, another major target of CDK4 is now known: CDK4 is also required to 128 ª 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd phosphorylate and activate the master G2/M transcription factor FOXM1 (Anders et al., 2011) (Figure 3), so that inhibition of CDK4 is also expected to arrest cells in G2, or…”
BackgroundInfluentialThe transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer
Bell, R. J. A., Rube, H. T., Kreig, A., Mancini, A., Fouse, S. D., Nagarajan, R. P., Choi, S., Hong, C., He, D., Pekmezci, M., et al. (2015) · Science · doi:10.1126/science.aab0015 · Cited by 566 · cited 2×
“preferentially recruited to this mutant site in various cells – similar mutations having also now been found in a range of different cancer types (Bell et al., 2015).”
BackgroundAnders, L., Ke, N., Hydbring, P., Choi, Y. J., Widlund, H. R., Chick, J. M., Zhai, H., Vidal, M., Gygi, S. P., Braun, P., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.001 · Cited by 543 · cited 7×
“However, another major target of CDK4 is now known: CDK4 is also required to 128 ª 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd phosphorylate and activate the master G2/M transcription factor FOXM1 (Anders et al., 2011) (Figure 3), so that inhibition of CDK4 is also expected to arrest cells in G2, or…”
BackgroundInfluentialRole of telomeres and telomerase in cancer
Shay, J. W., & Wright, W. E. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.10.001 · Cited by 523
Heaphy, C. M., Subhawong, A. P., Hong, S.-M., Goggins, M. G., Montgomery, E. A., Gabrielson, E., Netto, G. J., Epstein, J. I., Lotan, T. L., Westra, W. H., et al. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.06.018 · Cited by 516
Coppé, J.-P., Rodier, F., Patil, C. K., Freund, A., Desprez, P.-Y., & Campisi, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.257071 · Cited by 506
Melanoma: from mutations to medicine
Tsao, H., Chin, L., Garraway, L. A., & Fisher, D. E. (2012) · Genes & Development · doi:10.1101/gad.191999.112 · Cited by 496
Cellular senescence: a link between cancer and age-related degenerative disease?
Campisi, J., Andersen, J. K., Kapahi, P., & Melov, S. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.09.001 · Cited by 421 · cited 1×
“More recently, cell senescence has also become strongly implicated in aging, a topic beyond the present scope but well reviewed by others (Campisi et al., 2011; Chandler and Peters, 2013; Mu~noz-Esp ın and Serrano, 2014).”
BackgroundHuman cell senescence as a DNA damage response
Zglinicki, T. V., Saretzki, G., Ladhoff, J., Fagagna, F. D. D., & Jackson, S. P. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2004.09.034 · Cited by 419 · cited 3×
“Telomeres have a protective protein cap, the shelterin complex (Mart ınez and Blasco, 2011), but when a telomere reaches a critically short length, its cap is destabilized and the DNA end becomes exposed, leading to misrecognition of this end as a DNA double-strand break (Bartkova et al., 2006; Rossiello et al., 2014;…”
BackgroundSkp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence
Lin, H.-K., Chen, Z., Wang, G., Nardella, C., Lee, S.-W., Chan, C.-H., Yang, W.-L., Wang, J., Egia, A., Nakayama, K. I., et al. (2010) · Nature · doi:10.1038/nature08815 · Cited by 400 · cited 1×
“…can actively suppress senescence in various cells, at least in part by upregulation of SKP2, a component of a ubiquitin ligase that can mediate degradation of p21 (Figure 3) and another common CDK inhibitor p27 (Anders et al., 2011; Laoukili et al., 2007; Lin et al., 2010; Rovillain et al., 2011).”
POT1 loss-of-function variants predispose to familial melanoma
Robles-Espinoza, C. D., Harland, M., Ramsay, A. J., Aoude, L. G., Quesada, V., Ding, Z., Pooley, K. A., Pritchard, A. L., Tiffen, J. C., Petljak, M., et al. (2014) · Nature Genetics · doi:10.1038/ng.2947 · Cited by 391 · cited 1×
“Other such families had mutations in one of several shelterin (telomeric cap) components: POT1, ACD, and TERF2IP (Aoude et al., 2015; Robles-Espinoza et al., 2014; Shi et al., 2014).”
BackgroundAlimonti, A., Nardella, C., Chen, Z., Clohessy, J. G., Carracedo, A., Trotman, L. C., Cheng, K., Varmeh, S., Kozma, S. C., Thomas, G., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40535 · Cited by 374
Jacobs, J. J. L., Keblusek, P., Robanus-Maandag, E., Kristel, P., Lingbeek, M., Nederlof, P. M., van Welsem, T., van de Vijver, M. J., Koh, E. Y., Daley, G. Q., et al. (2000) · Nature Genetics · doi:10.1038/81583 · Cited by 368
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4
Program, N. C. S., Prickett, T. D., Agrawal, N. S., Wei, X., Yates, K. E., Lin, J. C., Wunderlich, J. R., Cronin, J. C., Cruz, P., Rosenberg, S. A., et al. (2009) · Nature Genetics · doi:10.1038/ng.438 · Cited by 352 · cited 3×
“It is involved in neural development and can promote melanoma cell proliferation (Prickett et al., 2009), while again NRG1 can stimulate glial cell (Sviderskaya et al., 2009) and melanoma cell proliferation (Zhang et al., 2012).”
BackgroundRare missense variants in POT1 predispose to familial cutaneous malignant melanoma
NCI DCEG Cancer Sequencing Working Group, Shi, J., Laboratory, N. D. C. G. R., French Familial Melanoma Study Group, Yang, X. R., Ballew, B., Rotunno, M., Calista, D., Fargnoli, M. C., Ghiorzo, P., et al. (2014) · Nature Genetics · doi:10.1038/ng.2941 · Cited by 331
MDM4 is a key therapeutic target in cutaneous melanoma
Gembarska, A., Luciani, F., Fedele, C., Russell, E. A., Dewaele, M., Villar, S., Zwolinska, A., Haupt, S., de Lange, J., Yip, D., et al. (2012) · Nature Medicine · doi:10.1038/nm.2863 · Cited by 327 · cited 2×
“However we also note one very common anti‐apoptotic change that is not known to be genetic, namely the upregulation (apparently post‐translational) of expression of the p53 antagonist MDM4 (MDMX) (Gembarska et al., 2012).”
BackgroundCoppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060301 · Cited by 302 · cited 1×
“IL6 and IL1; also including proteases such as MMP2, angiogenic factors like VEGFs, and other growth factors (Coppé et al., 2008; Kuilman et al., 2008).”
BackgroundSenescent cells develop a parp-1 and nuclear factor-κB-associated secretome (PNAS).
Ohanna, M., Giuliano, S., Bonet, C., Imbert, V., Hofman, V., Zangari, J., Bille, K., Robert, C., Bressac-de Paillerets, B., Hofman, P., et al. (2011) · Genes & Development · doi:10.1101/gad.625811 · Cited by 267
Suram, A., Kaplunov, J., Patel, P. L., Ruan, H., Cerutti, A., Boccardi, V., Fumagalli, M., Di Micco, R., Mirani, N., Gurung, R. L., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.132 · Cited by 227
Review: a meta‐analysis of GWAS and age‐associated diseases
Jeck, W. R., Siebold, A. P., & Sharpless, N. E. (2012) · Aging Cell · doi:10.1111/j.1474-9726.2012.00871.x · Cited by 204 · cited 2×
“p16 can be activated by induced telomere dysfunction (Jacobs and de Lange, 2005), and given also the genetic correlations of both p16 variants and telomere‐related variants with ageing (Jeck et al., 2012) (and with melanoma, as discussed later), it seems increasingly likely that p16‐mediated replicative senescence als…”
BackgroundNecessary and Sufficient Role for a Mitosis Skip in Senescence Induction
Johmura, Y., Shimada, M., Misaki, T., Naiki-Ito, A., Miyoshi, H., Motoyama, N., Ohtani, N., Hara, E., Nakamura, M., Morita, A., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.003 · Cited by 182 · cited 2×
“This may help to explain the occurrence of cells with giant or multiple nuclei, mitotic defects, and/or 4N DNA content in senescent cell populations (Gray-Schopfer et al., 2006; Johmura et al., 2014; Laoukili et al., 2007).”
BackgroundMC1R Is a Potent Regulator of PTEN after UV Exposure in Melanocytes
Cao, J., Wan, L., Hacker, E., Dai, X., Lenna, S., Jimenez-Cervantes, C., Wang, Y., Leslie, N. R., Xu, G. X., Widlund, H. R., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.08.010 · Cited by 144
Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis
Nogueira, C., Kim, K.-H., Sung, H., Paraiso, K. H. T., Dannenberg, J.-H., Bosenberg, M., Chin, L., & Kim, M. (2010) · Oncogene · doi:10.1038/onc.2010.349 · Cited by 108 · cited 1×
“Given these several potential antitumor effects, it is not surprising that Pten deletion within melanocytes in mice greatly accelerates the development of melanomas induced by activated Braf and (human) NRAS transgenes (Dankort et al., 2009; Nogueira et al., 2010).”
BackgroundBond, J. A., Haughton, M. F., Rowson, J. M., Smith, P. J., Gire, V., Wynford-Thomas, D., & Wyllie, F. S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.4.3103 · Cited by 104 · cited 5×
“disrupted without expressing TERT, for example in fibroblasts with the p16 and p53 pathways abrogated (Bond et al., 1999), or in human melanocytes lacking functional p16 (Sviderskaya et al.”
BackgroundInfluentialXia, J., Jia, P., Hutchinson, K. E., Dahlman, K. B., Johnson, D., Sosman, J., Pao, W., & Zhao, Z. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0804 · Cited by 94
DePinho, R. A., & Polyak, K. (2004) · Nature Genetics · doi:10.1038/ng0904-932 · Cited by 91
Cellular senescence mediated by p16INK4A-coupled miRNA pathways
Overhoff, M. G., Garbe, J. C., Koh, J., Stampfer, M. R., Beach, D. H., & Bishop, C. L. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1096 · Cited by 77 · cited 2×
“…new fields of research may enter the picture: for example, information is now emerging steadily about the roles of miRNAs and other non-coding RNAs in melanoma or in senescence, including p16-mediated senescence (Overhoff et al., 2014), miRNAs being another field omitted here for reasons of space.”
BackgroundCancer cell senescence: a new frontier in drug development
Cairney, C. J., Bilsland, A. E., Evans, T. R. J., Roffey, J., Bennett, D. C., Narita, M., Torrance, C. J., & Keith, W. N. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.01.019 · Cited by 50
Self-citation
Cited by
Goding, C. R., & Arnheiter, H. (2019) · Genes & Development · doi:10.1101/gad.324657.119 · Cited by 430
To clear, or not to clear (senescent cells)? That is the question
Lujambio, A. (2016) · BioEssays · doi:10.1002/bies.201670910 · Cited by 108
Chen, Z., Guo, Y., Zhao, D., Zou, Q., Yu, F., Zhang, L., & Xu, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.808208 · Cited by 87
“The p16INK4A protein is a CDK (cyclindependent kinase) inhibitor, and it functions as a predominant suppressor of melanoma (Krimpenfort et al., 2001; Sviderskaya et al., 2002; Goldstein et al., 2006; Bennett, 2015).”
Metadata
- Authors
- Bennett, D. C.
- Venue
- Pigment Cell & Melanoma Research
- Publisher
- Wiley
- Published
- 2015-11-18
- Volume
- 29
- Issue
- 2
- Pages
- 122-140
- ISSN
- 1755-1471 (ISSN-L)
- 1755-148X
- OpenAlex
- W1893275964
- Cited by
- 85
- References
- 52
- FWCI
- 7.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.